Alamri Faisal F, Almarghalani Daniyah A, Alraddadi Eman A, Alharbi Abdullah, Algarni Hajar S, Mulla Oyoon M, Alhazmi Abdullah M, Alotaibi Turki A, Beheiry Deema H, Alsubaie Abdullah S, Alkhiri Ahmed, Alatawi Yasser, Alzahrani Mohammad S, Hakami Alqassem Y, Alamri Aser, Al Sulaiman Khalid
Department of Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
King Salman Center for Disability Research, Riyadh, Saudi Arabia.
Saudi Pharm J. 2024 Jun;32(6):102082. doi: 10.1016/j.jsps.2024.102082. Epub 2024 Apr 22.
Glucose-Potassium Ratio (GPR) has emerged as a biomarker in several pathophysiological conditions. However, the association between GPR and long-term outcomes in stroke patients has not been investigated. Our study evaluated the applicability of baseline GPR as a predictive prognostic tool for clinical outcomes in ischemic stroke patients.
The multicenter retrospective cohort study included acute-subacute adult ischemic stroke patients who had their baseline serum GPR levels measured. Eligible patients were categorized into two sub-cohorts based on the baseline GPR levels (<1.67 vs. ≥ 1.67). The primary outcome was the incidence of 30-day hemorrhagic transformation, while stroke recurrence, and all-cause mortality within twelve months, were considered secondary.
Among 4083 patients screened, 1047 were included in the current study. In comparison with GPR < 1.67 group, patients with ≥ 1.67 GPR had a significantly higher ratio of all-cause mortality within twelve months (aHR 2.07 [95 % CI 1.21-3.75] = 0.01), and higher ratio of 30-day hemorrhagic transformation but failed to reach the statistical significance (aHR 1.60 [95 % CI 0.95-2.79], = 0.08).
Overall, baseline GPR serum is an independent predictor of all-cause mortality within twelve months in patients with acute and subacute ischemic stroke. Further clinical studies are necessary to validate these findings.
葡萄糖 - 钾比值(GPR)已成为多种病理生理状况下的生物标志物。然而,GPR与卒中患者长期预后之间的关联尚未得到研究。我们的研究评估了基线GPR作为缺血性卒中患者临床预后预测性预后工具的适用性。
这项多中心回顾性队列研究纳入了测量了基线血清GPR水平的急性 - 亚急性成年缺血性卒中患者。符合条件的患者根据基线GPR水平(<1.67与≥1.67)分为两个亚队列。主要结局是30天出血性转化的发生率,而卒中复发以及十二个月内的全因死亡率被视为次要结局。
在筛查的4083例患者中,1047例纳入本研究。与GPR <1.67组相比,GPR≥1.67的患者在十二个月内的全因死亡率显著更高(调整后风险比2.07 [95%置信区间1.21 - 3.75],P = 0.01),30天出血性转化的比例更高,但未达到统计学意义(调整后风险比1.60 [95%置信区间0.95 - 2.79],P = 0.08)。
总体而言,基线GPR血清是急性和亚急性缺血性卒中患者十二个月内全因死亡率的独立预测因素。需要进一步的临床研究来验证这些发现。